Biogen Inc
NASDAQ: BIIB
$164.89
-$0.90 (-0.5%)
Closing Price on November 14, 2024
BIIB Articles
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 29, 2014. They include AngloGold Ashanti, Twitter, Biogen Idec, Celgene, HomeAway and VMware.
Published:
In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six physicians. They favor four top stocks now as best positioned for continued...
Published:
In a new research report, analysts at Credit Suisse wonder if Apple's huge seven-for-one split may start a new trend. Here are some of the companies that they think may be ripe for a split.
Published:
Could stock splits be coming back in vogue? Apple finally announced a major stock split. What is amazing is that the split was so large, on a seven-for-one basis.
Published:
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of...
Published:
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Published:
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and...
Published:
Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs...
Published:
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated Outperform...
Published:
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
Published:
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, March 27, 2014. They include Apple, BlackBerry, Chesapeake Energy, Citigroup and King...
Published:
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
Published:
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms in Thursday, March 6, 2014. The include Biogen Idec, Exxon Mobil, MarkWest Energy and Yum! Brands.
Published: